TWi Biotechnology Past Earnings Performance
Past criteria checks 0/6
TWi Biotechnology has been growing earnings at an average annual rate of 16.9%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been declining at an average rate of 13.5% per year.
Key information
16.9%
Earnings growth rate
19.8%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | -13.5% |
| Return on equity | -47.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How TWi Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -78 | 16 | 70 |
| 31 Mar 23 | 0 | -77 | 16 | 72 |
| 31 Dec 22 | 0 | -76 | 16 | 75 |
| 30 Sep 22 | 0 | -78 | 15 | 75 |
| 30 Jun 22 | 0 | -79 | 14 | 75 |
| 31 Mar 22 | 33 | -47 | 14 | 71 |
| 31 Dec 21 | 66 | -15 | 14 | 67 |
| 30 Sep 21 | 66 | -23 | 14 | 73 |
| 30 Jun 21 | 66 | -31 | 14 | 78 |
| 31 Mar 21 | 34 | -66 | 14 | 82 |
| 31 Dec 20 | 1 | -102 | 14 | 85 |
| 30 Sep 20 | 6 | -101 | 15 | 86 |
| 30 Jun 20 | 11 | -100 | 16 | 87 |
| 31 Mar 20 | 10 | -106 | 18 | 92 |
| 31 Dec 19 | 10 | -112 | 19 | 97 |
| 30 Sep 19 | 17 | -110 | 21 | 95 |
| 30 Jun 19 | 24 | -109 | 23 | 93 |
| 31 Mar 19 | 25 | -111 | 22 | 96 |
| 31 Dec 18 | 26 | -113 | 21 | 99 |
| 30 Sep 18 | 32 | -123 | 19 | 110 |
| 30 Jun 18 | 38 | -133 | 17 | 122 |
| 31 Mar 18 | 56 | -119 | 17 | 117 |
| 31 Dec 17 | 75 | -105 | 16 | 112 |
| 30 Sep 17 | 57 | -98 | 16 | 103 |
| 30 Jun 17 | 39 | -91 | 15 | 95 |
| 31 Mar 17 | 19 | -104 | 15 | 100 |
| 31 Dec 16 | 0 | -118 | 14 | 104 |
| 30 Sep 16 | 8 | -118 | 12 | 113 |
| 30 Jun 16 | 16 | -118 | 10 | 123 |
| 31 Mar 16 | 16 | -126 | 11 | 123 |
| 31 Dec 15 | 16 | -133 | 12 | 123 |
| 31 Dec 14 | 0 | -97 | 10 | 88 |
| 31 Dec 13 | 4 | -100 | 9 | 95 |
Quality Earnings: 6610 is currently unprofitable.
Growing Profit Margin: 6610 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6610 is unprofitable, but has reduced losses over the past 5 years at a rate of 16.9% per year.
Accelerating Growth: Unable to compare 6610's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6610 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Return on Equity
High ROE: 6610 has a negative Return on Equity (-47.23%), as it is currently unprofitable.